Delays in diagnosis and bladder cancer mortality by Hollenbeck, Brent K. et al.
Delays in Diagnosis and Bladder Cancer
Mortality
Brent K. Hollenbeck, MD, MS1,2,3; Rodney L. Dunn, MS2; Zaojun Ye, MS2; John M. Hollingsworth, MD, MS2,4;
Ted A. Skolarus, MD2; Simon P. Kim, MD, MPH2; James E. Montie, MD1,2; Cheryl T. Lee, MD1; David P. Wood, Jr., MD1;
and David C. Miller, MD, MPH1,2,3
BACKGROUND: Mortality from invasive bladder cancer is common, even with high-quality care. Thus, the best oppor-
tunities to improve outcomes may precede the diagnosis. Although screening currently is not recommended, better
medical care of patients who are at risk (ie, those with hematuria) has the potential to improve outcomes. METHODS:
The authors used the Surveillance, Epidemiology, and End Results-Medicare linked database for the years 1992
through 2002 to identify 29,740 patients who had hematuria in the year before a bladder cancer diagnosis and
grouped them according to the interval between their first claim for hematuria and their bladder cancer diagnosis.
Cox proportional hazards models were fitted to assess relations between these intervals and bladder cancer mortal-
ity, adjusting first for patient demographics and then for disease severity. Adjusted logistic models were used to esti-
mate the patient’s probability of receiving a major intervention. RESULTS: Patients (n ¼ 2084) who had a delay of 9
months were more likely to die from bladder cancer compared with patients who were diagnosed within 3 months
(adjusted hazard ratio [HR], 1.34; 95% confidence interval [CI], 1.20-1.50). This risk was not markedly attenuated after
adjusting for disease stage and tumor grade (adjusted HR, 1.29; 95% CI, 1.14-1.45). In fact, the effect was strongest
among patients who had low-grade tumors (adjusted HR, 2.11; 95% CI, 1.69-2.64) and low-stage disease (ie, a tumor
[T] classification of Ta or tumor in situ; adjusted HR, 2.02; 95% CI, 1.54-2.64). CONCLUSIONS: A delay in the diagnosis
of bladder cancer increased the risk of death from disease independent of tumor grade and or disease stage. Under-
standing the mechanisms that underlie these delays may improve outcomes among patients with bladder cancer.
Cancer 2010;116:5235–42. VC 2010 American Cancer Society.
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Nearly 1 in 10 patients with hematuria have an associated life-threatening disease.1 However, although hematuria is a
common manifestation of an underlying bladder neoplasm, it is a symptom shared with many other diseases, including
urinary tract infection. Because of its lack of specificity, some physicians may procrastinate with regard to the evaluation
of hematuria,2 for which current clinical guidelines recommend urine cytologic evaluation, upper urinary tract imaging,
and cystoscopy.3 The implications of a delay in the diagnosis of bladder cancer are not entirely clear.4,5
Earlier evaluation and intervention for patients with bladder cancer potentially can improve their outcomes. For
example, delays in definitive treatment (ie, from transurethral resection to radical cystectomy) have been associated with
worse outcomes.6 On average, patients who wait for >3 months between diagnosis and radical cystectomy are at 20% to
90% greater risk of mortality,7,8 at 60% greater risk of disease progression,9 and are more likely to have advanced disease
(ie, with lymph node involvement).8-11 In this context, 1 potential mechanism to improve patient outcomes is to ensure
timely intervention as necessary.
However, even in the best of hands, a cure for many patients with bladder cancer remains elusive, and nearly 33% of
all patients die from disease within 5 years of the diagnosis.12 Invariably, tumor biology plays an important role in deter-
mining the ultimate outcome regardless of the type and timing of treatment. Thus, it seems logical that opportunities to
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improve bladder cancer outcomes may be greatest
upstream from the diagnosis. Screening for bladder cancer
may identify more patients at a curable stage of the dis-
ease, but this approach is not yet ready to be implemented
at the population level.13 Alternatively, better recognition
and timely intervention before the diagnosis afford the
possibility of immediate improvements in outcomes. For
this reason, we used national cancer registry data to evalu-
ate relations between a delay in diagnosis and outcomes
among patients with bladder cancer.
MATERIALS AND METHODS
Study Population
We used the Surveillance, Epidemiology, and End Results
(SEER)-Medicare linked database for the years 1992
through 2002 to identify patients with bladder cancer.
These files provide information onMedicare patients who
are included in SEER,14 which is a nationally representa-
tive collection of population-based registries of all inci-
dent cancers that comprised approximately 26% of the
US population by the end of the study period.15 For each
Medicare patient in SEER, the SEER-Medicare linked
files contain 100% of Medicare claims from the inpatient,
outpatient, and national claims history files. From these
files, all Medicare patients aged 66 years with incident
cases of bladder cancer were identified by the appropriate
code in SEER. Only fee-for-service beneficiaries with cov-
erage for both Parts A and B of Medicare were included in
this study.
Next, we identified 29,740 of 37,972 patients
(78%) who had a claim that included a physician-ascribed
diagnosis of hematuria (International Classification of
Diseases, Ninth Revision [ICD-9] diagnosis code 599.7x)
within the year preceding a bladder cancer diagnosis. The
initial claim for hematuria was determined according to
the claim that was the most removed in terms of date from
the date of the bladder cancer diagnosis within the 12-
month window. We limited our retrospection to 1 year
before diagnosis for 2 reasons. First, looking back further
would require additional patient exclusions, thereby
reducing our sample size and generalizability. For exam-
ple, a 2-year window would necessitate limiting our popu-
lation to patients aged 67 years to ensure that all
patients had similar entitlements to Medicare coverage
during the period at risk. Second, the vast majority of
patients (75%) aged70 years (those with at least 5-years
of prediagnosis claims) had their initial claim for hematu-
ria within the 12-month period before their bladder can-
cer diagnosis.
Finally, we sorted patients into 4 groups based on
the interval between the date of their initial claim for he-
maturia and the date of their bladder cancer diagnosis
(<3 months, 3 months to <6 months, 6 months to <9
months, and 9 months to 12 months). We chose this clas-
sification scheme for 2 reasons. First, the literature is
replete with studies that support a 3-month interval
between diagnosis and treatment as a clinically important
threshold, indicating that greater delays may have a nega-
tive impact on outcomes.6-10,16 Second, this methodology
enables us to contrast the extremes in the interval between
the initial hematuria claim and the bladder cancer diagno-
sis and to articulate more easily the clinical relevance of
the problem.
Outcomes
Our primary outcome was bladder cancer-specific mortal-
ity as determined by SEER’s cause-of-death variable.
Given concerns surrounding the attribution of the cause-
of-death,17 we also assessed all-cause mortality. Survival
time was measured from the date of bladder cancer diag-
nosis, as determined by the date of biopsy or transurethral
resection, to the date of death, and surviving patients were
censored on September 30, 2005 (ie, the date of the most
recent death). In addition, patients who died were cen-
sored for the cancer-specific survival analyses if their cause
of death site was listed as anything other than the urinary
system. Secondarily, we also identified the receipt of a
major medical intervention (as evidenced by a claim for
radical cystectomy, systemic chemotherapy, or radiation
therapy) in the inpatient, national claims history, and out-
patient files. All outcomes, for which the patient was the
unit of analysis, were measured between January 1, 1992
and December 31, 2005.
Statistical Analysis
For all of our analyses, our exposure was the interval
between the initial claim for hematuria and bladder cancer
diagnosis, which was divided into 3-month intervals (<3
months, 3 months to <6 months, 6 months to <9
months, and 9 months to 12 months). First, we examined
differences in patient demographics according to this
interval. Next, we evaluated the extent to which disease
characteristics and survival varied according to the inter-
val. For all of these comparisons, statistical inference was
made using chi-square tests or log-rank tests, as
appropriate.
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For the purpose of understanding the relation
between the delay interval and bladder cancer mortality,
we fit a Cox proportional hazards model adjusting for
patient characteristics, including patient age, sex, race,
and comorbidity. The last variable was identified using
healthcare encounters (both inpatient and outpatient) in
the 12-month period preceding the bladder cancer diag-
nosis using an adaptation of the Charlson Comorbidity
Index18 as described by Klabunde and colleagues.19 In
addition, we adjusted for socioeconomic status using a
composite measure assessed at the zip code level, as
described by Diez-Roux et al.20
To evaluate the extent to which differences in disease
severity might explain any disparity in survival because of
a delay in diagnosis, a second model was fit adjusting for
the above covariates and for cancer grade and stage. The
relative attenuation of the hazard ratio (HR) was meas-
ured as (HRR  HRF)/(HRR  1), where HRR is the
adjusted HR of mortality for diagnosis delay ignoring dis-
ease severity measures, and HRF is the HR for diagnosis
delay after including the disease severity measures.
For each of our secondary outcomes (all-cause mor-
tality and the use of major interventions), we fit separate
models adjusting for the same covariates that were used in
our primary analysis. For all Cox models, the assumption
of proportionality was confirmed by visual inspection of
the hazard plots and goodness-of-fit testing.21 The use of
a major medical intervention was determined by fitting
adjusted logistic models and then back-transforming these
models to estimate each patient’s probability of under-
going the intervention.
Then, we performed several sensitivity analyses to
assess the robustness of our findings. First, we adjusted
our final models for whether the patient underwent cys-
toscopy at the time (within 30 days) of the initial hematu-
ria claim. Second, we treated our time-to-diagnosis
exposure as a continuous variable in lieu of categorizing it
into 3-month groups. Third, we attempted to adjust for
the severity of hematuria (eg, gross vs microscopic); how-
ever, 99.95% of 353,091 claims that were submitted for
hematuria within national claims history files were for
ICD-9 code 599.7 (hematuria unspecified). Fourth, to
determine the extent to which lead-time bias might
account for any observed differences in survival between
groups (ie, patients with shorter intervals would appear to
have longer survival even if the actual survival times from
initial hematuria claim were equal), we assessed survival
from the date of first hematuria claim until death. Finally,
we assessed survival according to diagnosis delay among
patients with no comorbid conditions (ie, those in whom
the probability of unmeasured confounding is smallest).
In all patients, the magnitude and significance of the
effects were nearly identical to those in our primary
analyses.
All analyses were carried out using computerized sta-
tistical software (SAS Institute, Cary, NC). All tests were
2-tailed, and the probability of Type 1 error was set at .05.
The study protocol was approved by the Institutional
Review Board of the University of Michigan.
RESULTS
Of 29,826 patients with bladder cancer, we identified
7004 (24%) whose diagnosis was made 3 months after
an initial physician claim with a hematuria diagnosis,
including 2084 patients (7%) whose interval was 9
months. The median survival for the cohort ranged from
50.9 months for patients who had an interval 9 months
to 70.9 months for those whose diagnosis was made
within 3 months (log-rank P< .001). On the basis of our
sensitivity analysis assessing median survival from the first
hematuria claim until death, lead-time bias played a
minor role in explaining differences in survival between
the groups (<3-month group: survival, 70.9 months; 3 to
6-month group: survival, 62.6 months; 6 to 9-month
group: survival, 60.7 months; 9 to 12-month group: sur-
vival, 59.9 months; log-rank P < .001). Table 1 shows
that patients who had longer delays tended to be older
men with more comorbid illnesses. However, the distri-
butions of cancer grade and stage were similar across all
diagnostic delay intervals. Finally, almost all patients
(93.5%) underwent cystoscopy within 30 days of their
initial claim for hematuria, although small but significant
differences were evident according to delay intervals.
Table 2 highlights the finding that longer delays in
diagnosis were associated with increased risk of bladder
cancer-specific and all-cause mortality. Compared with
patients who were diagnosed within 3 months, patients
who had delays 9 months were 34% more likely to die
from bladder cancer after adjusting for patient demo-
graphics (adjusted HR, 1.34; 95% confidence interval
[CI], 1.20-1.50). After incorporating disease severity
measures into the model, the risk was attenuated by only
14.7%, suggesting that differences in tumor grade and
disease stage explained little of the observed differences in
bladder cancer mortality across diagnostic delay strata.
Among the patients who had no comorbid conditions,
those who had delays 9 months were 38% more likely
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to die from bladder cancer after adjusting for patient
demographics (adjusted HR, 1.38, 95% CI, 1.17-1.63)
compared with those who were diagnosed within 3
months.
Longer diagnostic intervals were associated most
strongly with bladder cancer-specific mortality among
patients with low-grade and low-stage disease (Table 3).
Among those with low-grade disease, patients who had a
delay 9 months were more than twice as likely to die
from bladder cancer compared with patients who had a
delay <3 months (adjusted HR, 2.11; 95% CI, 1.69-
2.64). The corresponding relation among patients who
had high-grade disease was more modest (adjusted HR,
1.10; 95% CI, 0.95-1.27). Similar relations were evident
for patients who had a diagnosis delay >6 months. For
our sensitivity analysis using the time between first hema-
turia claim and diagnosis as a continuous exposure, we
observed an increased risk of death from bladder cancer
(adjusted HR, 1.01; 95% CI, 1.01-1.03) and death from
all causes (adjusted HR, 1.01; 95% CI, 1.01-1.02). That
is, each day of delay was associated with an approximately
1% greater risk of death.
Compared with patients whose diagnosis was made
within 3 months of the initial claim for hematuria, those
who had a delay 9 months were more likely to undergo
radical cystectomy (5.8% vs 6.2%; P ¼ .04; c-index,
Table 1. Patient Characteristics According to the Interval Between an Initial Claim for Hematuria
and Bladder Cancer Diagnosis











No. of patients 22,736 2904 2016 2084
Median survival, mo 70.9 59.6 54.7 50.9 <.001
Age, y, % <.001
66-69 14.2 12.3 12.9 10.7
70-74 23.8 21.5 21.7 20.8
75-79 25.7 25.6 24.9 24.8
80-84 20.1 21.7 22.7 23.3
‡85 16.2 18.9 17.8 20.4
Women, % 27.4 27.9 26.2 23.5 <.001
Race, % <.001
White 94.1 91.6 91.7 92.2
Black 3.4 5.3 4.5 4.5
Other 2.5 3.1 3.8 3.3
Socioeconomic status, %
Low 32.5 33.8 35.6 33.5 .06
Medium 34.2 34.2 33.0 32.6
High 33.3 32.0 31.4 33.9
No. of comorbidities, % <.001
0 56.8 50.9 48.4 47.2
1 20.2 21.3 22.6 22.5
2 11.2 12.0 13.7 13.9
‡3 11.8 15.8 15.3 16.4
Tumor grade, % .11
Low 53.7 51.9 54.4 51.5
High 46.3 48.1 45.6 48.5
Tumor stage, % .66
Ta/Tis 52.6 52.8 54.1 52.3
T1 20.3 20.6 20.6 19.5
T2 17.5 17.2 16.6 17.5
‡T3 9.6 9.4 8.7 10.7
Cystoscopy within 30 d of initial
hematuria claim, %
97.4 95.0 94.7 95.3 <.001
Tis indicates tumor in situ.
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Table 2. Relation Between Delays in Diagnosis and Mortality
HR (95%CI)
Model Unadjusted Adjusteda Adjustedb
Cancer-specific mortality
Delay <3 mo 1.0 1.0 1.0
Delay 3 to <6 mo 1.09 (0.99-1.20) 1.00 (0.89-1.11) 1.05 (0.93-1.18)
Delay 6 to <9 mo 1.19 (1.07-1.33) 1.16 (1.03-1.31) 1.30 (1.15-1.48)
Delay 9-12 mo 1.39 (1.26-1.54) 1.34 (1.20-1.50) 1.29 (1.14-1.45)
All-cause mortality
Delay <3 mo 1.0 1.0 1.0
Delay 3 to <6 mo 1.13 (1.07-1.19) 1.06 (1.00-1.12) 1.06 (1.00-1.13)
Delay 6 to <9 mo 1.21 (1.14-1.29) 1.15 (1.07-1.23) 1.19 (1.11-1.28)
Delay 9-12 mo 1.28 (1.21-1.36) 1.15 (1.08-1.23) 1.12 (1.04-1.20)
HR indicates hazard ratio; CI, confidence interval.
a Adjusted for age, sex, race, socioeconomic status, and comorbidity.
b Adjusted for the same variables stated above plus grade and stage.
Table 3. Relation Between Diagnosis Delays and Cancer-Specific Mortality by Cancer Grade and Stage
HR (95% CI)
Stratified Model Unadjusted Adjusteda Adjustedb
Grade
Low-grade
Delay <3 mo 1.0 1.0 1.0
Delay 3 to <6 mo 1.19 (0.95-1.48) 1.03 (0.79-1.34) 1.05 (0.81-1.36)
Delay 6 to <9 mo 1.47 (1.17-1.86) 1.61 (1.26-2.07) 1.61 (1.25-2.06)
Delay 9-12 mo 2.31 (1.90-2.81) 2.21 (1.78-2.75) 2.11 (1.69-2.64)
High-grade
Delay <3 mo 1.0 1.0 1.0
Delay 3 to <6 mo 1.02 (0.92-1.15) 0.98 (0.86-1.11) 1.05 (0.93-1.20)
Delay 6 to <9 mo 1.13 (0.99-1.29) 1.07 (0.92-1.24) 1.21 (1.04-1.41)
Delay 9-12 mo 1.18 (1.04-1.33) 1.13 (0.98-1.30) 1.10 (0.95-1.27)
Tumor classification
Ta/Tis
Delay <3 mo 1.0 1.0 1.0
Delay 3 to <6 mo 1.46 (1.18-1.82) 1.29 (0.99-1.67) 1.26 (0.96-1.66)
Delay 6 to <9 mo 1.85 (1.47-2.33) 1.86 (1.44-2.42) 1.85 (1.40-2.45)
Delay 9-12 mo 2.07 (1.66-2.58) 2.22 (1.75-2.83) 2.02 (1.54-2.64)
T1
Delay <3 mo 1.0 1.0 1.0
Delay 3 to <6 mo 1.25 (1.00-1.57) 1.14 (0.87-1.49) 1.19 (0.91-1.56)
Delay 6 to <9 mo 1.31 (1.00-1.70) 1.39 (1.05-1.84) 1.40 (1.05-1.87)
Delay 9-12 mo 1.63 (1.28-2.07) 1.48 (1.12-1.96) 1.50 (1.12-1.99)
T2
Delay <3 mo 1.0 1.0 1.0
Delay 3 to <6 mo 0.99 (0.84-1.18) 0.87 (0.71-1.07) 0.90 (0.73-1.10)
Delay 6 to <9 mo 1.15 (0.94-1.40) 1.16 (0.92-1.45) 1.14 (0.90-1.44)
Delay 9-12 mo 1.37 (1.14-1.63) 1.23 (1.00-1.51) 1.25 (1.02-1.53)
‡T3
Delay <3 mo 1.0 1.0 1.0
Delay 3 to <6 mo 1.04 (0.87-1.23) 1.05 (0.87-1.28) 1.02 (0.83-1.25)
Delay 6 to <9 mo 1.11 (0.90-1.37) 1.08 (0.85-1.38) 1.12 (0.87-1.43)
Delay 9-12 mo 1.02 (0.83-1.23) 0.93 (0.74-1.16) 0.98 (0.78-1.23)
HR indicates hazard ratio; CI, confidence interval; Tis, tumor in situ.
a Adjusted for age, sex, race, socioeconomic status, and comorbidity.
b Adjusted for the same variables stated above plus stage (in grade strata) or grade (in stage strata).
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0.66) or any major intervention (8.6% vs 10.1%; P¼ .04;
c-index, 0.63) after adjusting for patient differences
(Fig. 1). Among the patients who underwent the interven-
tion, the median time from bladder cancer diagnosis to
radical cystectomy for those whose diagnosis was made
within 3 months was 2.4 months compared with
2.6 months for patients who had a delay9 months (log-
rank P ¼ .44). The corresponding times to any major
intervention were 2.3 months and 2.6 months, respec-
tively (log-rank P¼ .62).
DISCUSSION
Patients with protracted delays between an initial claim
for hematuria and the diagnosis of bladder cancer are at
34% higher risk of dying from the disease and are more
likely to undergo major interventions, including radical
cystectomy. Although the latter differences are of debata-
ble clinical significance, the observed mortality differences
are robust. The increasing risk of mortality with longer di-
agnosis delays was not directly attributable to greater dis-
ease severity as measured by cancer grade and stage.
Surprisingly, delays in diagnosis appeared to exert the
strongest effects among those with low-grade and low-
stage disease.
That diagnosis delays are associated with lower rates
of survival is not surprising in light of the rich literature
describing the effects of prolonged intervals between diag-
nosis and radical cystectomy.5,6,8,10,16 For example, in 1
study, patients who had treatment delays>3 months were
more than twice as likely to die from their cancers com-
pared with those who had more prompt intervention.16
However, although it is generally believed that such rela-
tions are mediated by disease progression, our data do not
necessarily support this mechanism upstream from the
cancer diagnosis. Patients who had more protracted inter-
vals between an initial claim for hematuria and bladder
cancer diagnosis had similar grade and stage distributions
relative to those with shorter intervals. Furthermore, we
observed only a 15% reduction in the risk of cancer-spe-
cific mortality after accounting for these disease severity
measures.
Although the mechanisms underlying these mortal-
ity differences are unclear, there are at least 2 possibilities.
On 1 hand, patients with longer diagnosis delays may
have access to care issues beyond those of insurance enti-
tlement that also translate into delays in definitive local
therapy for patients who need it. However, among the
patients who underwent major interventions, we observed
no differences in the time to treatment according to the
diagnostic delay interval, and in all patients, the median
time to treatment was<3 months.
Alternatively, the observed relations between diag-
nosis delay and mortality may reflect the quality of care
provided. Specifically, it is plausible that patients who
have more protracted delays may receive their care in
lower quality settings. For example, patients with more
pronounced delays were less likely to undergo cystoscopy
around the time of hematuria. Although differences in
cystoscopy use were quite small and lacked clinical signifi-
cance, they may reflect other disparities in quality (eg,
physician practice styles) that were not readily appreciable
in the data. This may explain why those with lower risk
bladder cancer (ie, low grade and stage) have the most to
lose. Arguably, the goal with these patients is to prevent
disease recurrence and progression, because those who
progress fare no better than those who present initially
with invasive disease.22 In lower risk patients, physician
decision making surrounding the nature and extent of
treatment likely plays a primary role in determining out-
comes, whereas the effects of tumor biology are more pro-
nounced for those who have muscle invasion. Examples in
which questionable decision making may contribute to
missing the window for cure include continued use of
intravesical therapy despite multiple failures or frequent
fulguration of recurrent disease without pathologic assess-
ment. Regardless, the finding that almost everyone with a
delay underwent cystoscopy within 30 days of their initial
hematuria claim means that many of these cancers
Figure 1. This bar chart illustrates the percentages of patients
undergoing radical cystectomy and receiving any aggressive
therapy (radical cystectomy, systemic chemotherapy, or radi-
ation therapy). Analyses were adjusted for age, sex, race,
socioeconomic status, and comorbidity. An increasing diag-
nostic delay interval was associated both with undergoing
radical cystectomy (P ¼ .04) and with the receipt any aggres-
sive therapy (P ¼ .04).
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presumably are being missed despite theoretically appro-
priate evaluation—a problem that might be tough to rem-
edy unless better diagnostic tools become available.
A central concern when using observational data is
the possibility that patient heterogeneity may explain in
part the relation between exposure and outcomes.23 Spe-
cifically, although observational studies are able to
account for measurable characteristics that mediate rela-
tions between diagnosis delay and mortality, they cannot
account for potentially important factors that are unmeas-
ured. For example, patients with protracted delays may
have more aggressive bladder cancers, which naturally
would result in higher disease mortality. However, we
addressed this limitation by using a clinical cancer registry
that captures both cancer grade and stage, arguably the
most important mediators of bladder cancer-specific sur-
vival.12,24 Furthermore, we used robust methods to adjust
for patient comorbidity19 and socioeconomic status,20 2
well described predictors of long-term mortality.25,26
Nonetheless, it is possible that unmeasured characteristics
of tumor biology, such as lymphovascular invasion27 and
microvessel density,28 may explain some of our findings
relative to the grade and stage effects. Perhaps it is such
unmeasured machinery that, over time, enables disease
progression and whose effects may be most apparent for
those with seemingly curable disease (eg, low grade and
stage).
Another concern centers on our use of the cause-of-
death variable as measured by SEER and the possibility of
attribution bias.17 Specifically, deaths among patients
with longer diagnosis delays may be attributed preferen-
tially to bladder cancer relative to those with shorter
delays. Although this theoretically is possible, we know of
no biologic rationale why such differential attribution
might exist. Furthermore, the approach used by the SEER
registries to identify cause of death has been well vetted in
patients with other nonhematopoietic malignancies,29,30
and its extension to the bladder cancer population seems
reasonable. Next, because we assessed survival from diag-
nosis (ie, the date of transurethral resection) to death, it is
possible that differences in lead time (ie, between the date
of hematuria and diagnosis) may explain part of the
observed survival differences between groups. However,
we assessed this as part of a sensitivity analysis and
observed that the survival benefit for those with the short-
est interval between hematuria and diagnosis persisted
even after considering the differences in lead time. A final
consideration stems from the use of the Medicare popula-
tion. Because we studied patients aged 66 years, our
findings may not be generalizable to a younger group.
However, because nearly 75% of bladder cancers occur in
Medicare-aged patients,15 our findings are pertinent to
(arguably) the most important group with the disease, and
their applicability to the larger population of patients with
bladder cancer seems appropriate.
In conclusion, nearly 1 in 4 patients who ultimately
are diagnosed with bladder cancer has a delay >3 months
between their first provider claim for hematuria and diag-
nosis. Those with more protracted delays have signifi-
cantly higher rates of mortality from the disease and are
more likely to undergo a major intervention, such as radi-
cal cystectomy. These mortality differences do not appear
to be caused by disease progression, at least as measured
by cancer grade and stage. Although the mechanisms
underlying this relation are unclear, future work should
explore both the evaluation of these patients upstream
from the diagnosis and the care provided to those with
lower risk disease downstream from the diagnosis, for
whom the delay seems to matter the most.
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